Andere talen Eisai Co., Ltd.

Aandelen

4523

JP3160400002

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6.545 ^JPY	-0,06%		+4,89%	-7,19%

24/04	Biogen verslaat kwartaalwinstramingen, verkoop Alzheimer medicijnen stijgt	RE
23/04	Medicijn tegen Alzheimer in VS vertraagd door scepticisme artsen	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024	25/04
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024	24/04
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	24/04
Alzheimer's drug adoption in US slowed by doctors' skepticism	23/04
BioArctic and Eisai sign research evaluation agreement regarding BAN2802	20/04
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802	20/04
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)	18/04
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan	17/04
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?	13/04
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics	03/04
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	01/04
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	01/04
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	01/04
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed	01/04
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	01/04
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical	29/03
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture	29/03
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024	29/03
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	25/03
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	22/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Eisai Co., Ltd.

Aandelen

4523

JP3160400002

Andere talen

Filters